CEL-SCI Corporation (CVM)

6.25
0.30 4.96
AMEX
Prev Close 5.95
Open 6.02
Day Low/High 5.80 / 6.50
52 Wk Low/High 0.82 / 4.44
Volume 612.58K
Exchange AMEX
Shares Outstanding 33.03B
Market Cap 196.55M
Div & Yield N.A. (N.A)

Latest News

CEL-SCI Selected By National Institutes Of Health To Showcase Its LEAPS Technology At BIO International Convention

CEL-SCI Selected By National Institutes Of Health To Showcase Its LEAPS Technology At BIO International Convention

CEL-SCI Corporation (NYSE American: CVM) today announced it has been selected by the U.

CEL-SCI's Scientific Article On Vaccines For Autoimmune Disease Published In Journal Of Clinical & Cellular Immunology

CEL-SCI's Scientific Article On Vaccines For Autoimmune Disease Published In Journal Of Clinical & Cellular Immunology

CEL-SCI Corporation (NYSE American:CVM) today announced the Journal of Clinical & Cellular Immunology has published an article titled, "Why Don't We Have a Vaccine Against Autoimmune Diseases?" co-written by Dr.

CEL-SCI Corporation Reports First Quarter Fiscal 2019 Financial Results

CEL-SCI Corporation Reports First Quarter Fiscal 2019 Financial Results

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2018.

CEL-SCI To Present At 2019 BIO CEO & Investor Conference

CEL-SCI To Present At 2019 BIO CEO & Investor Conference

CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, announced today that Geert Kersten, Chief Executive Officer, will be presenting at the 2019 BIO CEO & Investor Conference in New York, NY on Monday, February 11, 2018 at...

U.S. Patent Office Issues CEL-SCI Two Patents For Its LEAPS Vaccine Platform Technology

U.S. Patent Office Issues CEL-SCI Two Patents For Its LEAPS Vaccine Platform Technology

CEL-SCI Corporation (NYSE American: CVM) today announced the U.S.

CEL-SCI Regains Full Listing Compliance With NYSE American

CEL-SCI Regains Full Listing Compliance With NYSE American

CEL-SCI Corporation (NYSE American: CVM) today announced that it has received notification from the staff of the NYSE American, its current listing exchange, that the Company is now considered in full compliance with the continued listing requirements.

CEL-SCI Reports Fiscal 2018 Financial Results And Clinical & Corporate Developments

CEL-SCI Reports Fiscal 2018 Financial Results And Clinical & Corporate Developments

CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2018.

CEL-SCI Receives About $8 Million From Warrant Exercises

CEL-SCI Receives About $8 Million From Warrant Exercises

CEL-SCI Corporation (NYSE American: CVM) announced today it has received just under $8 million through the exercise of warrants to purchase shares of the Company's common stock during the past 3 months.

CEL-SCI Announces Warrants To Expire On October 11, 2018

CEL-SCI Announces Warrants To Expire On October 11, 2018

CEL-SCI Corporation (NYSE American: CVM) is advising the holders of its publicly traded warrants (NYSE American: CVM WS) that the warrants will expire and not be exercisable after 5:00 p.

CEL-SCI Receives $5.4 Million From Warrant Exercises

CEL-SCI Receives $5.4 Million From Warrant Exercises

CEL-SCI Corporation (NYSE American: CVM) announced today it has received $5,435,367 through the exercise of warrants to purchase shares of the Company's common stock during August through September 13, 2018.

NIH Selects CEL-SCI's LEAPS Rheumatoid Arthritis Vaccine For Commercialization Accelerator Program

NIH Selects CEL-SCI's LEAPS Rheumatoid Arthritis Vaccine For Commercialization Accelerator Program

CEL-SCI Corporation (NYSE American: CVM) announced today that the National Institutes of Health (NIH) selected CEL-SCI and its LEAPS* rheumatoid arthritis vaccine candidate as a Small Business Innovation Research/Small Business Technology Transfer...

CEL-SCI Corporation Releases Letter To Shareholders

CEL-SCI Corporation Releases Letter To Shareholders

The following letter was sent by CEL-SCI Corporation (NYSE American: CVM) to its shareholders for the upcoming annual meeting: Dear CEL-SCI Shareholders, Our singular goal right now is to reach the final data readout of the Phase 3 trial to establish the...

CEL-SCI Announces That The NYSE American Approves Plan

CEL-SCI Announces That The NYSE American Approves Plan

CEL-SCI Corporation (NYSE American: CVM) announces that the NYSE American (the "Exchange") has accepted the Company's plan to bring itself into compliance with the Exchange's continued listing standards.

CEL-SCI Reports Recent Data Review By The Independent Data Monitoring Committee For Its Pivotal Phase 3 Head And Neck Cancer Study

CEL-SCI Reports Recent Data Review By The Independent Data Monitoring Committee For Its Pivotal Phase 3 Head And Neck Cancer Study

CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection)...

CEL-SCI Corporation Reports Third Quarter Fiscal Year 2018 Financial Results

CEL-SCI Corporation Reports Third Quarter Fiscal Year 2018 Financial Results

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2018.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ELON, EVRI, GSK, ITGR, MRAM, NPO, PLNT, QIWI, RUN, SFM, WIT Downgrades: ALEX, CVM, METC, SBGI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

CEL-SCI Reports On NYSE American Noncompliance Notice And Compliance Plan

CEL-SCI Reports On NYSE American Noncompliance Notice And Compliance Plan

CEL-SCI Corporation (NYSE American: CVM) reported on a communication received today from the staff of the NYSE American, its current listing exchange, that it considered the Company to be noncompliant with certain listing requirements based on its...

CEL-SCI Corporation Issues Letter To Shareholders

CEL-SCI Corporation Issues Letter To Shareholders

CEL-SCI Corporation (NYSE American:CVM) today issued a letter to its shareholders.

CEL-SCI Announces The Closing Of Its $5 Million Registered Direct Offering

CEL-SCI Announces The Closing Of Its $5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE American: CVM) today announced that it has closed its previously announced registered direct offering and concurrent private placement with institutional investors.

CEL-SCI Announces $5 Million Registered Direct Offering

CEL-SCI Announces $5 Million Registered Direct Offering

CEL-SCI Corporation  (NYSE American: CVM) today announced it has entered into definitive agreements with institutional investors for an offering of shares of common stock with gross proceeds of approximately $5 million in a registered direct offering.

CEL-SCI Receives $2.1 Million From Warrant Exercises

CEL-SCI Receives $2.1 Million From Warrant Exercises

CEL-SCI Corporation (NYSE American: CVM), in response to shareholder questions, updates its shareholders on the amount of money received from warrant exercises since April 1, 2018.

Cel-Sci Wins Breach Of Contract Ruling Against Clinical Research Organization InVentiv, Now Known As Syneos Health

Cel-Sci Wins Breach Of Contract Ruling Against Clinical Research Organization InVentiv, Now Known As Syneos Health

CEL-SCI Corporation (NYSE American: CVM) announced today that after a four and a half year battle a decision has been delivered by the arbitrator in CEL-SCI's arbitration suit against clinical development giant inVentiv, now part of Syneos Health...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BPT, BRT, CALL, CVM, GCI, OCC, SNMP, WCFB, WYY Downgrades: CERC, IESC Initiations: GRNQ, OPRX Read on to get TheStreet Quant Ratings' detailed report:

CEL-SCI Corporation Issues Letter To Shareholders

CEL-SCI Corporation Issues Letter To Shareholders

CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.

U.S. Patent Office Allows New CEL-SCI Patents For LEAPS Vaccine Platform Technology

U.S. Patent Office Allows New CEL-SCI Patents For LEAPS Vaccine Platform Technology

CEL-SCI Corporation (NYSE American: CVM) today announced the U.S.

CEL-SCI To Present Today At The 8th Annual LD Micro Invitational

CEL-SCI To Present Today At The 8th Annual LD Micro Invitational

CEL-SCI Corporation (NYSE American: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting today, June 5, 2018 at 12:00 pm PT / 3:00 pm ET at the 8th annual LD Micro Invitational.

CEL-SCI Corporation To Present At The 8th Annual LD Micro Invitational

CEL-SCI Corporation To Present At The 8th Annual LD Micro Invitational

CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy biopharmaceutical company, today announced that it will be presenting at the 8th annual LD Micro Invitational on Tuesday, June 5 at 12:00 PM ET.